BridgeBio reports positive Phase 2 infigratinib results in achondroplasia; initiates hypochondroplasia study

BridgeBio Pharma, Inc.

Cohort 5 (0.25 mg/kg/day) showed sustained AHV increase: +2.51 cm/yr at Month 12, +2.50 cm/yr at Month 18 (p=0.0015).
Statistically significant improvement in body proportionality: upper/lower segment ratio 1.88 at Month 18 vs 2.02 baseline (p=0.001).
No treatment-related adverse events in Cohort 5; drug well-tolerated as single daily oral therapy.
First child consented in ACCEL observational study for hypochondroplasia; Phase 2/3 interventional study planned.
PROPEL 3 Phase 3 registrational enrollment on schedule, completion estimated by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.